3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
6
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Peritoneal Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Liver Diseases
1
Hemangiosarcoma
1
Gynecologic Cancer
1
Digestive System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Oxaliplatin
290
Capecitabine
206
Fluorouracil
181
Cisplatin
168
Docetaxel
138
S 1 (combination)
132
Paclitaxel
121
Leucovorin
116
Irinotecan
106
pembrolizumab
103
Trastuzumab
71
apatinib
56
Nivolumab
56
sintilimab
45
Drug Therapy
43
Surgical Procedures, Operative
37
Radiotherapy
37
Bevacizumab
37
Ramucirumab
34
titanium silicide
31
Hyperthermic Intraperitoneal Chemotherapy
30
Epirubicin
30
Carboplatin
30
tislelizumab
28
Cyclophosphamide
27
XELOX
24
Tegafur
23
Folfox protocol
22
Albumin-Bound Paclitaxel
22
camrelizumab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Stomach Neoplasms
×
genexol-PM
×
Clear all
NCT03618758
2023-12-05
IPLUS
Seoul National University Bundang Hospital
Phase 1/2
Completed
35 enrolled